HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

71.200

-4.900-6.44%

Volume:2.30M

Turnover:166.20M

Market Cap:14.17B

PE:-50.43

High:76.150

Open:76.000

Low:70.350

Close:76.100

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:1.02

T/O Rate:1.16%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.412

ROE:-27.61%

ROA:-9.92%

PB:9.59

PE(LYR):-50.43

PS:68.50

Loading ...

Overview Company News Filings

LEADS BIOLABS-B Surges Over 4% as Phase II Study for Biliary Tract Cancer Advances

Leads Biolabs Announces Phase II Biliary Tract Cancer Trial of Bispecific Antibody LBL-024 Moves to Expansion Phase

Bulletin Express

LEADS BIOLABS-B (09887): Phase II Study of Vilisin™ for Biliary Tract Cancer Progresses to Expansion Phase

Nanjing Leads Biolabs’ LBL-024 Phase II biliary tract cancer trial enters expansion phase

Stock Track | LEADS BIOLABS-B Soars 13.24% Intraday on AACR Abstract Acceptance and Research Validation

Leads Biolabs Maintains Stable Share Base in March 2026; Confirms Public-Float Compliance

Bulletin Express

LEADS BIOLABS-B Surges Over 10% in Morning Session Following AACR Abstract Acceptance

LEADS BIOLABS-B to Feature Two Preclinical Research Summaries at 2026 AACR Annual Meeting

Nanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters

Leads Biolabs Announces Board Reshuffle: Dr. Ni to Resign, Dr. Wu Nominated as Non-Executive Director, Nomination Committee Re-aligned

Bulletin Express

LEADS BIOLABS-B Nominates Wu Fenglan for Non-Executive Director Role

Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director

LEADS BIOLABS-B Reports 2025 Financial Results: Net Loss Narrows to 211 Million Yuan

Leads Biolabs 2025 Results: Revenue Reaches RMB177.26 Million on Up-Front Licensing; Net Loss Narrows 29.8% to RMB211.42 Million

Bulletin Express

Nanjing Leads Biolabs Co Ltd - FY Revenue RMB177.3 Million

THOMSON REUTERS

Nanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million

Leads Biolabs-B (09887) Schedules 27 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Dividend

Bulletin Express

Nanjing Leads Biolabs to hold board meeting on annual results and dividend proposal

Leads Biolabs doses first ESCC patient in Phase II Opamtistomig trial

Nanjing Leads Biolabs Joins Hang Seng Composite Index, Stock Connect List

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/09887/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":71.2,"timestamp":1787299688011,"preClose":76.1,"halted":0,"volume":2304503,"delay":0,"changeRate":-0.06438896189224694,"floatShares":198000000,"shares":199000000,"eps":-1.4119339130707524,"marketStatus":"Market Closed","change":-4.9,"latestTime":"08-21 16:08:08","open":76,"high":76.15,"low":70.35,"amount":166196792,"amplitude":0.076216,"askPrice":71.2,"askSize":1600,"bidPrice":71.15,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.3734266245324591,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":76.1,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":1.0243808093189501,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.411934,"volumeRatio":1.0243808093189501,"shares":199000000,"dividePrice":0,"high":76.15,"amplitude":0.076216,"preClose":76.1,"low":70.35,"week52Low":44.72,"pbRate":"9.59","psRate":"68.50","week52High":97.5,"institutionHeld":0,"latestPrice":71.2,"committee":-0.777778,"eps":-1.4119339130707524,"divideRate":0,"volume":2304503,"delay":0,"ttmEps":-1.3734266245324591,"open":76,"prevYearClose":51,"prevWeekClose":73.3,"prevMonthClose":53.4,"prevQuarterClose":49.32,"fiveDayClose":73.3,"twentyDayClose":62.45,"sixtyDayClose":62.95,"earningDate":1788105600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-08-21","current":-51.841139,"percent":0.129278,"low":-76.458084,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"high":-30.202688,"avg":-41.975218,"sd":9.878337,"marketCap":14161096160},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160}],"updateTime":1787452385708},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151050698","title":"LEADS BIOLABS-B Surges Over 4% as Phase II Study for Biliary Tract Cancer Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=1151050698","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151050698?lang=en_us&edition=fundamental","pubTime":"2026-04-09 09:44","pubTimestamp":1775699059,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) rose more than 4%, with the stock up 4.39% to HK$93.9 at the time of writing. The trading volume was HK$13.3778 million. On April 8, LEADS BIOLABS announced that the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","09887","HK0000500386.USD","VXUS","BK1161","HK0000252160.HKD","HK0000252152.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191731000","title":"Leads Biolabs Announces Phase II Biliary Tract Cancer Trial of Bispecific Antibody LBL-024 Moves to Expansion Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1191731000","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191731000?lang=en_us&edition=fundamental","pubTime":"2026-04-08 16:41","pubTimestamp":1775637669,"startTime":"0","endTime":"0","summary":"On 8 April 2026, Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) reported that its Phase II clinical study of Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, for first-line treatment of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147799498","title":"LEADS BIOLABS-B (09887): Phase II Study of Vilisin™ for Biliary Tract Cancer Progresses to Expansion Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1147799498","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147799498?lang=en_us&edition=fundamental","pubTime":"2026-04-08 16:38","pubTimestamp":1775637503,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the Phase II clinical study evaluating Vilisin™ (PD-L1/4-1BB bispecific antibody Opatisumimab, LBL-024) as a first-line treatment for advanced biliary tract...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4588","09887","TM","BK4555","BK4604","HK0000252152.HKD","BK4585","03160","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625619919","title":"Nanjing Leads Biolabs’ LBL-024 Phase II biliary tract cancer trial enters expansion phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619919","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625619919?lang=en_us&edition=fundamental","pubTime":"2026-04-08 16:33","pubTimestamp":1775637235,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs reported Phase II study of Opamtistomig , its PD-L1/4-1BB bispecific antibody, for first-line advanced biliary tract cancer has moved into expansion phase.Safety run-in phase completed preliminary assessment in 20 patients, supporting continuation on tolerability.Early efficacy readout showed an encouraging trend in tumor shrinkage, without disclosing detailed response figures.First patient has been enrolled in expansion phase as trial accelerates across multiple hospitals in China.Results have been presented as preliminary findings from safety run-in phase, with expansion-phase data expected in future updates.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL9tz0L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","BK1161","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192002926","title":"Stock Track | LEADS BIOLABS-B Soars 13.24% Intraday on AACR Abstract Acceptance and Research Validation","url":"https://stock-news.laohu8.com/highlight/detail?id=1192002926","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192002926?lang=en_us&edition=fundamental","pubTime":"2026-04-01 12:34","pubTimestamp":1775018058,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) saw its shares soar 13.24% during intraday trading on Wednesday.The surge follows the company's announcement that two abstracts detailing preclinical pipeline research results...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164371785","title":"Leads Biolabs Maintains Stable Share Base in March 2026; Confirms Public-Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1164371785","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164371785?lang=en_us&edition=fundamental","pubTime":"2026-04-01 11:06","pubTimestamp":1775012798,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. reported no movements in either authorised or issued share capital for the month ended 31 March 2026, according to its latest monthly return filed with Hong Kong...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106696968","title":"LEADS BIOLABS-B Surges Over 10% in Morning Session Following AACR Abstract Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1106696968","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106696968?lang=en_us&edition=fundamental","pubTime":"2026-04-01 10:18","pubTimestamp":1775009902,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) saw its shares rise more than 10% during the morning trading session. At the time of writing, the stock was up 8.99%, trading at HKD 80.65, with a turnover of HKD 32.19...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252152.HKD","VXUS","HK0000500386.USD","BK4585","BK1161","HK0000252160.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178094448","title":"LEADS BIOLABS-B to Feature Two Preclinical Research Summaries at 2026 AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1178094448","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178094448?lang=en_us&edition=fundamental","pubTime":"2026-03-31 17:00","pubTimestamp":1774947626,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that two preclinical pipeline research summaries will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The meeting is...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252152.HKD","HK0000500386.USD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623304255","title":"Nanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters","url":"https://stock-news.laohu8.com/highlight/detail?id=2623304255","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623304255?lang=en_us&edition=fundamental","pubTime":"2026-03-31 16:55","pubTimestamp":1774947327,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs disclosed two preclinical cancer drug candidates accepted for poster presentation at 2026 AACR Annual Meeting in San Diego on April 17-22, 2026.Data will be presented in the future on April 21, 2026 from 2:00 p.m. to 5:00 p.m. PT.LBL-054 TDC showed strong anti-tumor activity in preclinical models with a tolerability profile that supported repeat dosing in non-human primates.LBL-061 showed broad anti-tumor effects in preclinical studies with immune-activating features, supported by tolerability in non-human primates.Update positions Leads Biolabs to advance its T cell engager-drug conjugate and bispecific ADC programs, supporting its strategy across antibody and ADC platforms.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL4zJN1s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","BK1161","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102586833","title":"Leads Biolabs Announces Board Reshuffle: Dr. Ni to Resign, Dr. Wu Nominated as Non-Executive Director, Nomination Committee Re-aligned","url":"https://stock-news.laohu8.com/highlight/detail?id=1102586833","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102586833?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:04","pubTimestamp":1774609494,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”) reported three board-level changes that will take effect or be confirmed on 27 March 2026. Resignation of Non-Executive Director   • Dr. Ni Jia will...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116228132","title":"LEADS BIOLABS-B Nominates Wu Fenglan for Non-Executive Director Role","url":"https://stock-news.laohu8.com/highlight/detail?id=1116228132","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116228132?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:00","pubTimestamp":1774609235,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that Dr. Ni Jia has tendered her resignation as a non-executive director of the company, effective March 27, 2026. Following the recommendation of the board's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252152.HKD","HK0000500386.USD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622284948","title":"Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director","url":"https://stock-news.laohu8.com/highlight/detail?id=2622284948","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622284948?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:54","pubTimestamp":1774608885,"startTime":"0","endTime":"0","summary":"Non-executive director Ni Jia resigned, effective March 27, 2026.The board nominated Wu Fenglan as a non-executive director, subject to shareholder approval at the AGM.Wu previously served as a scientist at GlaxoSmithKline, and later held roles at Zai Lab, China Renaissance, and Gritgen Therapeutics.She joined Shanghai Zhengxingu Investment Management in October 2025 as a managing director focused on innovative drug investments.Nomination Committee member Zhang Hongbing was appointed chair, replacing Kang Xiaoqiang who remains a committee member.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL2Y01zT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109981661.USD","IE00B3T34201.USD","LU0575583348.USD","HK0000252160.HKD","LU1035777561.USD","LU0225771236.USD","LU0545562505.USD","BK1574","SGXZ57979304.SGD","LU0289739699.SGD","09887","LU0971552673.USD","LU1228905037.USD","LU1228905540.USD","LU1670756490.USD","LU2488822045.USD","BK1161","IE00BQJZX424.USD","LU1400636657.SGD","LU0306806265.USD","LU0058720904.USD","LU0211331839.USD","LU0225284248.USD","IE00BWDBJ516.SGD","LU0161305163.EUR","LU0306807586.USD","LU1481599808.USD","HK0000500386.USD","LU1302929846.USD","LU0203345920.USD","LU0971552830.HKD","LU1645745479.HKD","SG9999001176.SGD","BK1588","GSK.UK","LU0321505868.SGD","LU1309081286.SGD","LU1064927863.SGD","LU1481600234.SGD","LU0321505439.SGD","IE0034235071.USD","LU1983299246.USD","09688","LU0985481810.HKD","SG9999013999.USD","LU1202635105.USD","SG9999001176.USD","LU1046248800.SGD","LU1400636491.USD","LU1015430645.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124822191","title":"LEADS BIOLABS-B Reports 2025 Financial Results: Net Loss Narrows to 211 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1124822191","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124822191?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:11","pubTimestamp":1774602704,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced its financial results for the year 2025. The company reported revenue of approximately 177 million yuan. Research and development costs reached about 289 million...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000500386.USD","09887","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181768552","title":"Leads Biolabs 2025 Results: Revenue Reaches RMB177.26 Million on Up-Front Licensing; Net Loss Narrows 29.8% to RMB211.42 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1181768552","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181768552?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:04","pubTimestamp":1774602242,"startTime":"0","endTime":"0","summary":"Leads Biolabs (Nanjing Leads Biolabs Co., Ltd.) released its audited 2025 annual results. Financial Highlights   • Revenue: RMB177.26 million, versus zero in 2024, driven entirely by upfront and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622841100","title":"Nanjing Leads Biolabs Co Ltd - FY Revenue RMB177.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622841100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622841100?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:02","pubTimestamp":1774602122,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F04E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","BK1161","HK0000252152.HKD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622841469","title":"Nanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622841469","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622841469?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:01","pubTimestamp":1774602109,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB177.3 million.Research and development costs rose 55.7% to RMB289.1 million, driven by higher CMC milestone expenses tied to preparation for the LBL-024 BLA submission, as well as increased clinical development and preclinical spending.Administrative expenses fell 5.7% to RMB82.7 million, mainly due to lower share-based compensation, partly offset by higher listing and compliance-related costs.Loss for the year narrowed 29.8% to RMB211.4 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8jwpM6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158227991","title":"Leads Biolabs-B (09887) Schedules 27 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1158227991","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158227991?lang=en_us&edition=fundamental","pubTime":"2026-03-17 16:43","pubTimestamp":1773737026,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (stock name: Leads Biolabs-B; stock code: 09887) has announced that its board of directors will convene on Friday, 27 March 2026. The agenda includes: 1. Approval and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620442566","title":"Nanjing Leads Biolabs to hold board meeting on annual results and dividend proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2620442566","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620442566?lang=en_us&edition=fundamental","pubTime":"2026-03-17 16:31","pubTimestamp":1773736295,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs will hold a board meeting on 27 March 2026 to consider and approve its annual results for the year ended 31 December 2025. The board will also consider a dividend recommendation at the same meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL5hBv4Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000252152.HKD","09887","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618617560","title":"Leads Biolabs doses first ESCC patient in Phase II Opamtistomig trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617560","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618617560?lang=en_us&edition=fundamental","pubTime":"2026-03-09 14:28","pubTimestamp":1773037739,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. reported that the first patient has been dosed in an open-label, multi-center Phase II clinical study of opamtistomig , a PD-L1/4-1BB bispecific antibody, as first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma in China. The study is led by Professor Shen Lin of Beijing Cancer Hospital and will assess the drug’s efficacy and safety across multiple hospitals. No trial results were presented in the announcement; results are expected to be reported in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL9DLhvK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618261504","title":"Nanjing Leads Biolabs Joins Hang Seng Composite Index, Stock Connect List","url":"https://stock-news.laohu8.com/highlight/detail?id=2618261504","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618261504?lang=en_us&edition=fundamental","pubTime":"2026-03-09 11:09","pubTimestamp":1773025761,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs  said its shares will be included as a constituent of the Hang Seng Composite Index and added to the Stock Connect Southbound Trading Link, according to a March 6 Hong Kong bourse filing.Shares of the clinical-stage biotech company gained nearly 5% in Monday morning trade.The inclusion will take effect March 9, allowing eligible mainland investors to trade the company's Hong Kong-listed shares through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09887","HSCI","BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":131,"code":"91000000","status":"200"}]}}